(Q53194698)
English
Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-
scientific article published in January 2015
Statements
Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single- (English)
Won Park
Sang Joon Lee
Jihye Yun
Dae Hyun Yoo
1 January 2015
11 Suppl 1
S25-31
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference